Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Charles River Laboratories International Stock Quote

Charles River Laboratories International (NYSE: CRL)

$229.70
(-0.2%)
-$0.40
Price as of April 18, 2024, 1:22 p.m. ET

Charles River Laboratories International Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
CRL +11.68% +70.26% +11.22% +946%
S&P +20.88% +72.88% +11.56% +248%

Charles River Laboratories International Company Info

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment consists of the commercial production and sale of research models, research products, and the provision of services related to the maintenance and monitoring of research models and the management of the clients’ research operations. The Discovery and Safety Assessment segment offers integrated drug discovery services directed at the identification, screening, and selection of a lead compound for drug development and offers safety assessment services, including bioanalysis, drug metabolism, pharmacokinetics, toxicology, and pathology. The Manufacturing Support segment consists of Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services, Biologics Solutions, which performs specialized testing of biologics as well as contract development and manufacturing, and Avian Vaccine Services, which supplies specific-pathogen-free chicken eggs and chickens. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.